http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Transgene Completes Safety and Tolerability Assessment of TG4001 in Combination with Avelumab in Phase 1b Part of Trial in HPV-Positive Cancer Patients
-
Transgene Announces Financial Calendar for 2019
-
Transgene Announces Upcoming Investor Meetings
-
Transgene - Positive Results from Phase 1 Clinical Trial of TG1050 in Chronic Hepatitis B Presented at the AASLD Liver Meeting 2018
-
Transgene and BioInvent Present Positive Data at the SITC, Supporting the Co-development of a Next-generation Oncolytic Virus Encoding for an Anti-CTLA-4 Antibody
-
Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference
-
Transgene and BioInvent Present Positive Data at the SITC, Supporting the Co-Development of a Next-Generation Oncolytic Virus Encoding for an Anti-CTLA-4 Antibody
-
NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC’s AI and Transgene’s myvac™ platform
-
Transgene : €26.6 Million in Cash and Cash Equivalents as of September 30, 2018
-
First Patient Dosed in a Phase 1/2 Trial of Transgene’s Oncolytic Virus TG6002 Administered Intravenously in Patients with Advanced Gastrointestinal Tumors
-
Transgene to Present Positive Results from Phase 1b Trial of TG1050 in Patients with Chronic Hepatitis B at Upcoming AASLD Liver Meeting 2018
-
Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference
-
Transgene Unveils myvacTM, an Individualized Immunotherapy against Solid Tumors
-
Transgene Presents 2018 Half-Year Results and Business Update
-
Transgene Presents 2018 Half-Year Results and Business Update
-
Transgene Announces Upcoming Investor Meetings
-
Transgene Completes the Sale of the Greater China Rights of TG6002 and TG1050 to Tasly Biopharmaceuticals for $48 Million in Newly-Issued Shares
-
Transgene and Tasly Biopharmaceuticals Conclude Strategic Agreements for the Rights of Transgene’s Virus-Based Immunotherapies TG6002 and TG1050 in Greater China
-
Transgene’s Lead Oncolytic Virus Pexa-Vec Triggers Strong Anti-Tumor Immunity after Intravenous Administration
-
Transgene Announces Upcoming Investor Meetings
-
Transgene to Present New Clinical Data on Oncolytic Virus Pexa-Vec at ASCO 2018
-
Transgene: Availability of Preparatory Documents for the Combined General Meeting (Ordinary and Extraordinary Sessions) of May 23, 2018
-
Transgene: €35.6 Million in Cash and Cash Equivalents as of March 31, 2018
-
Transgene Presents Data on a Novel Viral Vector with Remarkable Anticancer Activity at AACR 2018
-
Transgene to Announce Major Clinical Results in 2018 and Achieve Promising Progress on Its New Oncolytic Viruses
-
Transgene to Present Data on a Novel Viral Vector with Superior Anti-Cancer Immunotherapeutic Activity at AACR 2018
-
First Chronic Hepatitis B Patient Dosed in China in a Phase 1 Trial of T101 (Transgene’s TG1050 Technology)
-
First Patient Dosed in a Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC)
-
Transgene Announces Financial Calendar for 2018
-
Transgene Announces Upcoming Investor Meetings
-
BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors
-
Transgene Successfully Raises € 14.4 Million from U.S. and European Investors
-
Transgene to Present Additional Immunology Data from the TIME trial with TG4010 in patients with advanced lung cancer at SITC 2017
-
Transgene: First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma
-
TG1050 is Well Tolerated and Induces a Strong Specific Immune Response in Patients with Chronic Hepatitis B
-
Transgene: Third Quarter Marked by Progress in Clinical Development and Research
-
Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B
-
Transgene: Peer Reviewed Scientific Publications Highlight TG4010’s Ability to Induce Broad CD8+ Responses and its Synergistic Effects in Combination with Immune Checkpoint Inhibitors
-
Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors
-
Transgene Launches Invir.IOTM, its Integrated Platform for the Next Generation of Multifunctional Oncolytic Viruses
-
Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
-
Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
-
Transgene: First Half-Year 2017 in Line with Our Objectives: All Clinical Programs Progressing and New Collaboration Agreements Signed
-
Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer (NSCLC)
-
Transgene and Institut Bergonié Present a Poster on the METROmaJX Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) at ESMO 2017 Congress
-
Transgene Announces Upcoming Investor Meetings
-
Transgene: First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer
-
Transgene Announces Cancer Research Publication Confirming the Potential of its Next Generation Armed Engineered Oncolytic Virus
-
Servier and Transgene Have Become Partners to Apply Viral Vectorization Technology to the Engineering of Allogenic CAR-T
-
Transgene Hosts Immuno-Oncology R&D Day Focused on Modulating the Tumor Micro-Environment in Paris
